Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 494
- Registration Number
- NCT01250379
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 688
- Registration Number
- NCT01250119
A Study of RO5185426 in Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Drug: RO5185426
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 374
- Registration Number
- NCT01248936
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Phase 3
Completed
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: OcrelizumabDrug: Interferon beta-1aDrug: Ocrelizumab-matching placeboDrug: Interferon beta-1a-matching placebo
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 821
- Registration Number
- NCT01247324
- Locations
- 🇺🇸
Northwestern University; Dept. of Neurology, Chicago, Illinois, United States
🇺🇸The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
🇺🇸Uni of Vermont Medical Center;, Burlington, Vermont, United States
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT01245439
A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
Phase 2
Completed
- Conditions
- Coronary Heart Disease, Graft Occlusion, Vascular
- Interventions
- Drug: RO4905417Drug: Placebo
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 384
- Registration Number
- NCT01245634
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
Phase 3
Completed
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1021
- Registration Number
- NCT01239732
Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253
Phase 3
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT01237496
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 597
- Registration Number
- NCT01235585
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: RO4917838Drug: Placebo
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 595
- Registration Number
- NCT01235520
© Copyright 2025. All Rights Reserved by MedPath